Effectiveness of Daily Chlorhexidine Bathing and Antibiotic and Proton Pump Inhibitor (PPI) Stewardship in Preventing Transmission and Infection Caused by Carbapenemase-Producing Enterobacteriaceae (CPE)

This multicenter, cluster-randomized crossover trial aims to evaluate the effectiveness and safety of a bundled intervention-including daily chlorhexidine bathing and targeted antimicrobial and proton pump inhibitor (PPI) stewardship-for preventing colonization and infection caused by carbapenemase-producing Enterobacteriaceae (CPE) in intensive care units (ICUs) across three university-affiliated hospitals in South Korea.
Each hospital will include two ICUs, randomized to either the intervention or control group for six months, followed by a crossover. The intervention group will receive daily bathing using no-rinse, 4% chlorhexidine gluconate (CHG)-impregnated washcloths along with antimicrobial and PPI stewardship focused on reducing unnecessary carbapenem and PPI use. The control group will receive standard bathing without chlorhexidine, while receiving the same stewardship interventions as the intervention group.
Primary outcomes include the incidence and prevalence of CPE colonization and CPE-attributable healthcare-associated infections such as bloodstream infections, hospital-acquired pneumonia, and urinary tract infections. Secondary outcomes include evaluation of residual CHG skin concentrations, comparison with CHG minimum inhibitory concentrations (MICs) of CPE isolates, impact of feedback on adherence to bathing protocols, and assessment of adverse skin reactions to CHG bathing.
Findings from this study are expected to provide evidence-based guidance on the effectiveness and feasibility of combining daily chlorhexidine bathing with no-rinse, 4% CHG-impregnated washcloths and stewardship interventions to control the spread of CPE in high-risk healthcare settings.

开始日期2025-07-14

申办/合作机构

GangNeung Asan Hospital

[+1]

KCT0009610

/ Not yet recruiting临床4期IIT

A single-arm, open-label study evaluating safety and efficacy of switching treatment to Enped tab (entecavir) in patients with chronic hepatitis B treated with Baraclude tab (ETV)

开始日期2024-08-12

申办/合作机构

GangNeung Asan Hospital

KCT0009588

/ Not yet recruitingN/AIIT

Advancement of Breath-Guided Virtual Reality for Pain and Anxiety Relief in Cancer Patients Undergoing Systemic Chemotherapy

开始日期2024-07-01

申办/合作机构

GangNeung Asan Hospital

100 项与 GangNeung Asan Hospital 相关的临床结果

登录后查看更多信息

0 项与 GangNeung Asan Hospital 相关的专利（医药）

登录后查看更多信息

892

项与 GangNeung Asan Hospital 相关的文献（医药）

2026-05-05·EUROPEAN HEART JOURNAL

Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial

Article

作者: Jang, Jae-Sik ; Bae, Jang-Whan ; Lee, Se-Whan ; Wee, Seong-Bong ; Park, Duk-Woo ; Park, Hanbit ; Bae, Jae Seok ; Suh, Jung-Won ; Lee, Jin Bae ; Kang, Do-Yoon ; Won, Hoyoun ; Suh, Jon ; Cho, Jang Hyun ; Yun, Sung-Cheol ; Park, Sangwoo ; Park, Kyoung-Ha ; Rha, Seung-Woon ; Oh, Jun-Hyok ; Choi, Jaewoong ; Park, Chul Soo ; Her, Sung-Ho ; Lee, Cheol Hyun ; Ahn, Young Keun ; Kang, Se Hun ; Ahn, Jung-Min ; Kwon, Osung ; Lee, Bong-Ki ; Cho, Young-Rak ; Park, Seung-Jung

Abstract:

Background and Aims:

Limited data exist on optimal antiplatelet strategies for high-risk patients undergoing complex percutaneous coronary intervention (PCI). This study aimed to investigate the efficacy and safety of tailored antiplatelet treatment with temporal modulation of the intensity of platelet inhibition in patients undergoing complex high-risk PCI.

Methods:

We randomly assigned 2018 patients with high-risk anatomical or clinical characteristics undergoing complex PCI to a tailored antiplatelet strategy with early escalation (low-dose ticagrelor at 60 mg twice daily plus aspirin <6 months) and late de-escalation (clopidogrel monotherapy >6 months) or dual antiplatelet therapy (clopidogrel plus aspirin for 12 months). The primary outcome was a composite of death from any cause, myocardial infarction, stroke, stent thrombosis, unplanned urgent revascularization, and clinically relevant bleeding (Bleeding Academic Research Consortium Type 2, 3, or 5) at 12 months.

Results:

The mean age was 64.0 years, 22.6% had left main PCI, 19.5% had complex bifurcation PCI, 84.1% had diffuse long lesions, 93.7% had multivessel PCI, and 36.7% had medically treated diabetes. At 12 months, a primary outcome event occurred in 105 patients (10.5%) assigned to tailored antiplatelet therapy and in 89 patients (8.8%) assigned to dual antiplatelet therapy [hazard ratio, 1.19; 95% confidence interval (CI), 0.90–1.58; P = .21]. The incidence of major ischaemic events appeared to be similar in both groups. The incidence of clinically relevant bleeding at 12 months was 7.2% in the tailored-therapy group and 4.8% in the dual-therapy group (difference, 2.45% points; 95% CI, 0.37–4.53).

Conclusions:

Among high-risk patients undergoing complex PCI, tailored antiplatelet strategy with early escalation and late de-escalation, as compared with dual antiplatelet therapy, did not decrease the incidence of primary net adverse events at 12 months.

Clinical Trial Registration:

ClinicalTrials.gov number, NCT03465644.

2026-05-01·STROKE

Outcomes and Safety of Revascularization Approaches for Stroke Related to Isolated Vertebral Artery Occlusions (BRAVO)

Article

作者: Heldner, Mirjam R. ; Giacobazzi, Laura ; Grisendi, Ilaria ; Truessel, Simon ; Nolte, Christian H. ; Gensicke, Henrik ; Tariq, Muhammad Bilal ; Nguyen, Thanh N. ; Pezzini, Alessandro ; Molina, Carlos A. ; Picchetto, Livio ; Clark, Judith ; Friedrich Scheitz, Jan ; Sykora, Marek ; Boehme, Christian ; Riegler, Christoph ; Puetz, Volker ; Pascarella, Rosario ; Pallesen, Lars-Peder ; Ryan, Dylan ; Gralla, Jan ; Bianco, Giovanni ; Abrahamson, Margareta ; Knoflach, Michael ; Caparros, François ; Leker, Ronen ; Engelter, Stefan T. ; Siegler, James E. ; Zini, Andrea ; Ahmad, Mohammad J. ; Rizzo, Federica ; Mordasini, Pasquale ; Ribo, Marc ; Nordanstig, Annika ; Napoli, Manuela ; Bigliardi, Guido ; Flottmann, Fabian ; Patel, Parth ; Salerno, Alexander ; Carrera, Emmanuel ; Simonnet, Fanny ; Kim, Jong S. ; Machi, Paolo ; Curtze, Sami ; Jeong, Soo ; Cordonnier, Charlotte ; Abdalkader, Mohamad ; Mac Grory, Brian ; Zamzam, Ahmad ; Maffei, Stefania ; Bernardo Escribano Paredes, José ; Ferrari, Julia ; Marto, Joao Pedro ; Strambo, Davide ; Henon, Hilde ; Fiehler, Jens ; Mazini, Bianca ; Nahhas, Michael ; Wischmann, Johannes ; Zedde, Marialuisa ; Wegener, Susanne ; Padjen, Visnja ; Migliaccio, Ludovica ; Frediani, Luca ; Cereda, Carlo W. ; Dunet, Vincent ; Baumgartner, Philipp ; Michel, Patrik ; Kellert, Lars ; Min, Jiangyong ; Dhar, Srishti ; Arnold, Marcel ; Krebs, Stefan ; Saliou, Guillaume ; Antonenko, Kateryna ; Gentile, Mauro

BACKGROUND::

The best revascularization strategy for acute ischemic stroke from isolated vertebral artery occlusion remains unclear.

METHODS::

This retrospective, international, multicenter cohort study included patients from 30 comprehensive stroke centers across Europe (n=23), North America (n=5), and Asia (n=2) between 2016 and 2022. Eligible patients presented with acute ischemic stroke within 24 hours of last seen well and had imaging-confirmed isolated vertebral artery occlusion. Two treatment comparisons were analyzed: intravenous thrombolysis (IVT)-only versus conservative treatment (Cx), and endovascular treatment (EVT)±IVT versus medical management (Cx and IVT). The primary outcome was the shift in 3-month modified Rankin Scale (mRS) score; secondary outcomes included early neurological improvement (24-hour-delta National Institutes of Health Stroke Scale score), recanalization, early neurological deterioration of ischemic origin, symptomatic intracerebral hemorrhage, and 3-month mortality. Analyses were adjusted using inverse probability of treatment weighting (IPTW).

RESULTS::

Among 494 patients, 143 (29%) received Cx, 218 (44%) IVT-only, and 133 (27%) EVT±IVT. Compared with Cx, IVT-only showed similar 3-month mRS score (IPTW-adjusted odds ratio [aOR] mRS shift score, 1.32 [95% CI, 0.80–2.18]), greater early neurological improvement (IPTW-adjusted-β coefficient, −1 [95% CI, −2.05 to 0.05]), and higher recanalization rates (IPTW-aOR, 4.33 [95% CI, 1.36–13.78]). Compared with MM (=IVT+Cx), EVT±IVT was associated with an unfavorable mRS shift score (IPTW-aOR mRS shift score, 0.51 [95% CI, 0.35–0.74]), higher early neurological deterioration of ischemic origin (IPTW-aOR, 9.06 [95% CI, 2.86–28.67]), and symptomatic intracerebral hemorrhage (IPTW-aOR, 6.05 [95% CI, 1.14–32.1]) though recanalization was over 4-fold higher (OR, 4.64 [95% CI, 1.90–11.33]). Patients with National Institutes of Health Stroke Scale score ≥10 showed point estimates favoring EVT+IVT ( Pinteraction =0.025).

CONCLUSIONS::

IVT-only appeared safe and was associated with better early recovery and recanalization. EVT±IVT showed overall worse outcomes, potentially due to increased early neurological deterioration of ischemic origin and symptomatic intracerebral hemorrhage rates, but may confer benefit in moderate-to-severe strokes, warranting prospective trials in symptomatic isolated vertebral artery occlusion.

2026-04-30·Journal of Neurogastroenterology and Motility

Real‑world Application of the International Anorectal Physiology Working Group Standardized Protocol and London Classification: A Multi‑country Cross‑sectional Survey of Anorectal Manometry Practice in Asia

Article

作者: Seo, Myeongsook ; Park, Seon-Young ; Sohn, Chong Il ; Choi, Soo In ; Choi, Suck Chei ; Lee, Han Hee ; Lee, Ju Yup ; Kim, Jong Wook ; Jung, Kee Wook

Background/Aims:

: The International Anorectal Physiology Working Group (IAPWG) has proposed a standardized protocol and the London classification to enhance the consistency and diagnostic accuracy of anorectal manometry (ARM). However, real-world adoption in Asian countries has not been systematically assessed. This study aims to evaluate current ARM practices and adherence to the IAPWG protocol across Asian centers.

Methods:

: A cross-sectional, 50-item web-based survey was distributed to gastroenterologists and motility specialists practicing in Asian countries.

Results:

: Thirty-one centers from 8 countries responded (20 in Korea, 3 in Japan, 2 in Taiwan, 1 in China, and 7 in other countries). High-resolution ARM was used in 80.6% of centers, primarily with solid-state catheters. While all centers performed rest and short squeeze maneuvers, only 58.1% conducted all maneuvers recommended by the IAPWG protocol. Considerable variation was observed in test methodology and interpretation, including definitions of resting pressure, squeeze duration, push maneuver repetition, and rectal balloon volume for rectoanal inhibitory reflex. For balloon expulsion and rectal sensory testing, centers differed in patient positioning, balloon type, inflation methods, and threshold definitions. Only 38.7% of centers reported having institutional normative values for test interpretation, and 64.5% applied the London classification.

Conclusions:

: Across Asian centers, ARM practice shows marked regional variation and incomplete implementation of the IAPWG standardized protocol and London classification, highlighting persistent gaps in standardization. Strengthening procedural guidance, regionally appropriate normative data, and interpretation criteria through coordinated education and international collaboration is needed to support more consistent and clinically meaningful use of ARM in routine practice.

项与 GangNeung Asan Hospital 相关的新闻（医药）

2023-01-05

·PRNewswire

WAYCEN, the first medical AI company to win 4 CES 2023 innovation awards "Proved K-Medtech"

Company specialized in AI Medtech, WAYCEN, won CES innovation awards for two years in a row WAYCEN swept CES 2023 innovation awards with medical AI products, collaborated with the medical staff SEOUL, South Korea, Jan. 5, 2023 /PRNewswire/ -- The company specialized in AI Medtech, WAYCEN (CEO Kyungnam Kim) made splendid achievements of winning four CES innovation awards for the first time among medical AI companies ahead of 'CES 2023', the world's largest electronics exhibition, which will be held in Las Vegas, United States, in next January. According to the 'CES 2023' award results announced by the Consumer Technology Association (CTA) on the 16th, WAYCEN won four innovation awards in WAYMED Cough, WAYMED Endo PRO, and WAYMED EBUS. By receiving two awards each in the digital healthcare and software&mobile apps sectors, it showed the technology leadership of K-medtech. Winning these awards means that WAYCEN has been recognized globally for its technical expertise in the real-time image analysis technology and medical big data analysis technology. Winning two awards solely for the products utilizing the real-time image analysis technology is to highlight innovations in WAYCEN's medical AI solution lineup. In addition, the three awarded products have been developed through joint research with the medical staff. It speaks volumes within the medical industry that medical professionals and AI-specialized company jointly developed clinically useful products through technical verifications and accomplished such great performance. WAYMED Cough is the world's first AI-based self-screening app service that enables the examination of a patient's respiratory health through an app. This service is the result of joint research by the research team led by Professor Kyeongmin Moon (Department of Pulmonology) at GangNeung Asan Hospital and Doctor Jinhee Jeon (JIMT CEO). Since it analyzes a user's respiratory health based on AI and helps people in any gender or age to easily manage respiratory health, the product was honored to win awards in two sectors (Digital health, Software & Mobile apps) for the CES 2023 innovation awards. WAYMED Endo, which won the CEO 2022 innovation award first in the industry for the technology that grafts AI technology to an endoscope, was advanced with the collaboration technology and won innovation awards for two years in a row. WAYMED Endo is an endoscopic image analysis software product that was jointly researched through the study with Professor Jie-hyun Kim, Department of Gastroenterology at Gangnam Severance Hospital. While endoscopy is in progress in an endoscopy room, AI detects abnormal areas (bumps or dents) in real time so that the medical staff can check the abnormal areas in the endoscopy room immediately. WAYMED EBUS is a solution that analyzes endobronchial ultrasound endoscopy images in real time and judges whether malignant lung cancer metastasis has occurred. This is also the solution that utilizes WAYCEN's real-time image analysis technology and is the result of joint research with the research team led by Professors Eun Young Kim and Seung Hyeon Yong of Department of Pulmonology at Severance Hospital. As it helps sort lymph nodes in need of biopsies in EBUS-TBNA tests, which take a lot of time and effort, using AI technology, this saves time and cost dramatically. This led to the recognition in innovativeness. Based on its unrivaled technology, WAYCEN was selected as the "Country Representative Innovation Company 1000" and Top 4 in the global healthcare award, "Medtech Innovator APAC", within 3 years after the foundation. WAYCEN is continuing its unwavering efforts as the unrivaled global company within the medical AI industry. ▶ WAYCEN Introduction Established in 2019, WAYCEN is a company specialized in the next-generation medical AI (artificial intelligence). Based on the AI technology with its root in deep learning, it develops and studies solutions that contribute to full-cycle treatments. Only within 3 years after foundation, WAYCEN possesses approximately 30 radiology-related patents, and is conducting AI-based medical joint research with various leading university hospitals in Korea. Also, it is the AI medtech-specialized company that was selected as the "Country Representative Innovation Company 1000'" and "MEDTECH INNOVATOR APAC TOP 4". WAYCEN does not stop developing the global top AI technology, but also strives to use our AI medical technology in medical sites efficiently and develop technology that can contribute to save people's lives. ▶ WAYMED Cough Introduction WAYMED Cough is an AI respiratory system self-screening app that records a user's coughing, respiratory, and vocal sounds through a smartphone and analyzes using AI. This product is the result of joint research by the research team led by Professor Kyeongmin Moon of Department of Pulmonology at GangNeung Asan Hospital and Doctor Jinhee Jeon (JIMT CEO) under the support for data center hospitals. Its service is currently uploaded on Google Play Store and App Store. Product introduction video: ▶ WAYMED Endo Introduction WAYMED Endo is a solution that performs colonoscopy/endoscopy and analyzes videos in real time based on AI simultaneously. Developed through joint research with Professor Jie-hyun Kim, Department of Gastroenterology at Gangnam Severance Hospital, WAYMED Endo, by mounting the AI engine that studied colonoscopy/endoscopy images and videos, provides functions to detect abnormal inside an endoscopic patient's digestive system in real time and notify it to the medical staff. WAYMED Endo can be used without Internet connection, and is medical image analysis software that can be used by connecting regardless of the brand of the endoscopic equipment. Product demo video: ▶ WAYMED EBUS Introduction WAYMED EBUS is a medical AI solution that analyzes bronchial ultrasound endoscopy images in real time to determine the metastasis status of a malignant lung cancer. Based on the patented WAYCEN's AI technology, it detects minute features of malignant lymph nodes that cannot be recognized visually and can analyze much more information quickly, which helps precise lung cancer diagnosis. This solution was jointly conducted with the research team led by Professors Eun Young Kim and Seung Hyeon Yong of Department of Pulmonology at Severance Hospital, and was published in the SCIE international scholarly journal, Translational Lung Cancer Research (TLCR) last February. Product demo video: ▶ CES Innovation Award Introduction The CES Innovation Award is an international award given to products with excellent technology, design, and innovativeness among the ones released to the market for the first time of that year. Divided into 28 protect categories, it is an annual award for innovative technical products for users, companies, and institutes. Professional judges in various industries including designers, engineers, and journalists, judge entries based on innovation, engineering, function, aesthetics, and design. Winning an innovation award means the technology is considered that the technology is unique and innovative in certain aspects, and a product with such characteristics is evaluated as being in the front line of the next-generation technology. SOURCE Waycen

100 项与 GangNeung Asan Hospital 相关的药物交易

登录后查看更多信息

100 项与 GangNeung Asan Hospital 相关的转化医学

登录后查看更多信息